Policy & Regulation
Captivate Bio to Distribute denovoMATRIX Cell Manufacturing Products in North America Under New Pact
6 April 2021 - - US-based scientific cell culture solutions provider Captivate Bio has signed a distribution agreement with German biotechnology company denovoMATRIX GmbH, which designs modular, biomimetic coatings for adherent cell manufacturing, the company said.

Captivate Bio will become the North American distributor of myMATRIX products including the innovative screenMATRIX and myMATRIXMSC as well as the newly released myMATRIXiPSC cultureware.

denovoMATRIX technologies are chemically defined, animal component-free and mimic functional features of the cellular microenvironment making them key tools in translational research and in accelerating the path to market for those in the cellular agriculture industry.

myMATRIX iPSC and myMATRIX MSC are pre-coated, ready-to-use consumables that promote chemically defined cell adhesion and expansion in serum-free, xeno-free iPSC and MSC culture applications.

screenMATRIX is a 96-well microplate system, pre-coated with various coatings to rapidly identify the functionally optimized coatings for any specific cell type.

denovoMATRIX is an extracellular matrix engineering company that enables the acceleration of cell-based therapies and development in stem cell research.

The company leverages chemical synthesis, stem cell biology and design thinking to build a platform of biomaterials which address major life science challenges.

By providing both cell-based therapy companies and translational researchers with solutions, denovoMATRIX is at the forefront of innovation in biomaterials.

Captivate Bio is a privately held scientific solutions provider specializing in the commercialization and distribution of high-quality reagents and custom cell culture media services for the research, therapeutic, and healthcare communities.

Current product offering includes viral transport media and collection kits plus classical cell culture media, fetal bovine serum, human platelet lysate, and a portfolio of custom media and small molecules for basic research, stem cell research, cell therapy, cytogenetics, and emerging markets such as cellular agriculture.


Related Headlines